Graphic | 1994 vs. 10 U.S. companies with the highest revenue in 2023

Gelonghui May 20 | Since the 1990s, the business field has undergone tremendous changes

Gelonghui, May 20 | Since the 1990s, the business world has undergone tremendous changes.
According to Fortune 2023 data. The chart below shows the 10 U.S. companies with the highest revenue in 1994 and 2023.
It\’s important to note that the 1994 data are not adjusted for inflation.
Before the big tech companies, three major automakers dominated the U.S. business landscape.
In 1994, General Motors and Ford ranked first and second with annual revenues of US$155 billion and US$128 billion respectively.
The annual revenues of Exxon and Mobil before the merger were US$102 billion and US$60 billion respectively. They ranked third and eighth respectively.
The TOP10 also includes Walmart ($83 billion), AT&T ($75 billion), General Electric ($65 billion), IBM ($64 billion), bankrupt veteran retailer Sears ($55 billion) and the largest tobacco company in the United States, Philip Morris ($54 billion).
By 2023, Walmart will become the company with the highest annual revenue in the United States, reaching US$611 billion.
Among large technology companies, Amazon (USD 514 billion), Apple (USD 394 billion), and Google parent company Alphabet (USD 283 billion) ranked second, fourth, and eighth respectively.
The TOP10 also includes the merged Exxon Mobil ($414 billion), UnitedHealth ($324 billion), CVS Health ($322 billion), Berkshire Hathaway ($302 billion), and the largest pharmaceutical distributor in the United States. McKesson ($264 billion) and Chevron ($246 billion).
The 10 highest-grossing companies have combined revenue of $3.7 trillion.

Like (0)
Previous May 20, 2024 4:56 pm
Next May 20, 2024 4:56 pm

Related posts

  • European stocks collectively opened lower, with the Stoxx Europe 50 index falling 0.80%

    The European Stoxx 50 index fell 0.80%, the German DAX index fell 0.83%, the British FTSE 100 index fell 0.78%, and the French CAC 40 index fell 0.62%.

    US Stocks Focus May 24, 2024
  • Axiscades Technologies subsidiary secures ₹90 crore order from BEL

    Axiscades Technologies Ltd’s subsidiary, Mistral Solutions, secured an order worth ₹90 crore from Bharat Electronics Limited for the design, development, and supply of eight Radar Processing Systems. The company said, these systems are intended for the Arudhra Medium Powered Radar (MPR), a 4D Radar capable of automatic detection, and tracking of various aerial targets.

    US Stocks Focus May 27, 2024
  • Buzzing stocks.Stocks that will see action today: May 2, 2024

    Godrej family announced a family settlement under which Adi Godrej and Nadir Godrej will control the listed companies in the group while Jamshyd Godrej and Nyrika Holkar will control Godrej Enterprises comprising Godrej & Boyce and its affiliates. The listed entities under Godrej Industries Group (GIG) are Godrej Industries, Godrej Consumer Products, Godrej Properties, Godrej Agrovet and Astec Lifesciences.

    US Stocks Focus May 3, 2024
  • Evergrande Real Estate and others were forced to execute 370 million yuan, and the total number of executions exceeded 52.8 billion.

    Risk information shows that Evergrande Real Estate Group Co., Ltd. currently has more than 680 pieces of information on persons subject to execution, and the total amount subject to execution exceeds 52.8 billion yuan. In addition, the company also has information on multiple consumption restriction orders, dishonest persons (Laolai) and final cases.

    US Stocks Focus April 25, 2024
  • The vaccine market is turbulent, and Zhifei Biotech’s “big brother” status is difficult to maintain

    For stock trading, please read Jin Qilin analyst research reports. They are authoritative, professional, timely and comprehensive, helping you to tap potential theme opportunities! Source: Financial Investment News Financial Investment News reporter Chen Yuhe After Zhifei Biotechnology (300122), the “vaccine brother”, released its 2023 annual report, its stock price continued to fall. Some market participants attributed its falling stock price to its high reliance on foreign supplies. Business is linked to the gradually revealed decline in performance. In recent years, the vaccine market has been changing. On the one hand, the once \”hot-selling\” nine-price HPV vaccine is no longer hard to find. On the other hand, various good news about the domestically produced nine-price HPV vaccine continue to spread, attracting a lot of attention. Institutions pay great attention to its listing process. Zhifei Bio\’s growth capability indicators Zhi Fei Bio\’s stock price continues to fall. The annual report shows that in 2023, Zhi Fei Bio\’s operating income was 52.918 billion yuan, a year-on-year increase of 38.3%; it achieved net profit attributable to the parent company of 8.07 billion yuan, a…

    US Stocks Focus April 25, 2024